180 related articles for article (PubMed ID: 36867557)
1. CAR T-cell therapy for CLL: a new addition to our treatment toolbox?
Iovino L; Shadman M
Clin Adv Hematol Oncol; 2023 Mar; 21(3):134-141. PubMed ID: 36867557
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
Iovino L; Shadman M
Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
[TBL] [Abstract][Full Text] [Related]
4. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
[TBL] [Abstract][Full Text] [Related]
5. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
6. Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
Smolewski P; Robak T
Acta Haematol; 2021; 144(4):365-379. PubMed ID: 33238270
[TBL] [Abstract][Full Text] [Related]
7. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
9. Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
Shadman M; Maloney DG
Hematol Oncol Clin North Am; 2021 Aug; 35(4):847-862. PubMed ID: 34174989
[TBL] [Abstract][Full Text] [Related]
10. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
11. Accelerated Chronic Lymphocytic Leukemia and Richter Transformation in the Era of Novel Agents.
Levy Yurkovski I; Tadmor T
Acta Haematol; 2024; 147(1):73-83. PubMed ID: 37666234
[TBL] [Abstract][Full Text] [Related]
12. [Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].
Gong JJ; Yin QS; Li MJ; Ai H; Wang Q; Chen L; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):750-754. PubMed ID: 31648477
[No Abstract] [Full Text] [Related]
13. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
14. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
15. Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
Wiedmeier-Nutor J; Leis J
Curr Treat Options Oncol; 2022 Jun; 23(6):904-919. PubMed ID: 35435617
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
[TBL] [Abstract][Full Text] [Related]
17. SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.
Burke JM
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):427-435. PubMed ID: 35577753
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.
Zou Y; Xu W; Li J
J Hematol Oncol; 2018 Nov; 11(1):130. PubMed ID: 30458878
[TBL] [Abstract][Full Text] [Related]
19. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Wolska-Washer A; Robak T
Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
[TBL] [Abstract][Full Text] [Related]
20. How and when I do allogeneic transplant in CLL.
Gribben JG
Blood; 2018 Jul; 132(1):31-39. PubMed ID: 29752258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]